Search Result

Results for "

thrombus formation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apoptosis (1) Calcium Channel (2) Cathepsin (1) Endogenous Metabolite (3) ERK (1) Factor Xa (6) Factor XI (2) Integrin (5) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) MMP (1) NADPH Oxidase (1) p38 MAPK (1) PDI (2) Phosphodiesterase (PDE) (1) PKC (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (1) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (2) Reference Standards (1) TGF-beta/Smad (1) Thrombin (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (23) Inflammation/Immunology (2)

By Targets:

5-HT Receptor (1)

Apoptosis (1)

Calcium Channel (2)

Cathepsin (1)

Endogenous Metabolite (3)

ERK (1)

Factor Xa (6)

Factor XI (2)

Integrin (5)

Isotope-Labeled Compounds (1)

Mitochondrial Metabolism (1)

MMP (1)

NADPH Oxidase (1)

p38 MAPK (1)

PDI (2)

Phosphodiesterase (PDE) (1)

PKC (1)

Platelet-activating Factor Receptor (PAFR) (1)

Potassium Channel (1)

Prostaglandin Receptor (2)

Protease Activated Receptor (PAR) (2)

Reference Standards (1)

TGF-beta/Smad (1)

Thrombin (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (23)

Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107588

TC-I 15 2 Publications Verification	Integrin	Cardiovascular Disease
TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .

HY-13965

Parmodulin 2 5 Publications Verification ML161	Protease Activated Receptor (PAR)	Cardiovascular Disease
Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC₅₀ of 0.26 μM . Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo .

HY-114086

ML359	PDI	Cardiovascular Disease
ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC₅₀ of 250 nM. ML359 can prevent thrombus formation in vivo .

HY-P5542

Vicatertide SB-01; Peniel 2000	Factor Xa TGF-beta/Smad	Inflammation/Immunology
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a K_a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .

HY-P3012

Cathepsin G	Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP	Inflammation/Immunology
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .

HY-111447

VAS 3947	NADPH Oxidase Apoptosis	Cardiovascular Disease Cancer
VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .

HY-10267

Eribaxaban PD-0348292	Factor Xa	Cardiovascular Disease
Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a K_i value of 0.32 nM. Eribaxaban reduces thrombus formation .

HY-W654264

2-Methylbutyrylcarnitine chloride	Endogenous Metabolite Integrin	Cardiovascular Disease
2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .

HY-170655

PDI-IN-4	PDI Integrin	Cardiovascular Disease
PDI-IN-4 (Compound 14d) is an inhibitor of protein disulfide isomerase, with an IC₅₀ value of 0.48 μM. PDI-IN-4 suppresses platelet aggregation and thrombus formation by attenuating GPIIb/IIIa activation without significantly causing cytotoxicity. PDI-IN-4 can be used in research on thrombosis .

HY-P991124

Cenvacibart REGN-7508	Factor XI	Cardiovascular Disease
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .

HY-116400

BN 50341	Calcium Channel Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
BN 50341 is an orally active anticalcic agent and a benzazepine derivative. BN 50341 decreases the in vivo electrically induced thrombus formation in rat or guinea-pig artery and can be utilized in cardiovascular research .

HY-10281

YM-60828 methanesulfonate	Factor Xa	Cardiovascular Disease
YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-101727

Nexopamil racemate	Calcium Channel 5-HT Receptor	Cardiovascular Disease
Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca ²⁺/5-HT₂ antagonist on thrombus formation in vivo and on platelet aggregation in vitro.

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-167736

(2R)-Naroparcil	Others	Others
(2R)-Naroparcil is an isomer of Naroparcil, a 4-methylumbelliferyl beta-D-xyloside analog that plays a role in promoting vascular smooth muscle cell proliferation and has been shown to inhibit thrombus formation in the Wessler slough model.

HY-123641

Celikalim Way 120491	Potassium Channel	Cardiovascular Disease
Celikalim (Way 120491) is an antihypertensive agent. Celikalim lowers blood pressure through opening potassium channelsin vascular smooth muscle. Celikalim can inhibit white thrombus formation. Celikalim is a potent potassium opener in dog model. Celikalim can be studied in thrombosis-related research .

HY-P3082

SKF 106760	Endogenous Metabolite	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

HY-123400A

iso-Samixogrel iso-DTTX30; iso-DT-TX 30 SE	Prostaglandin Receptor	Cardiovascular Disease
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.

HY-10279

YM-60828 hydrochloride	Factor Xa	Cardiovascular Disease
YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-182420

DJT06001	Factor Xa	Cardiovascular Disease
DJT06001 is an orally active, highly selective Factor Xa inhibitor. DJT06001 shows inhibition with K_i of 0.99 nM, IC₅₀ of 2.53 nM in prothrombinase complex and 3.33 nM in human plasma. DJT06001 dose-dependently prolongs PT and APTT, inhibits thrombus formation in vivo. DJT06001 can be used for the research of thromboembolic diseases .

HY-N18868

1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine PC(16:0/8:0)	Endogenous Metabolite	Cardiovascular Disease
1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine (PC(16:0/8:0)) is a phosphatidylcholine glycerophospholipid. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine promotes platelet aggregation and flow-induced platelet-dependent thrombus formation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is a valid biomarker for CAD risk, severity, and subtype differentiation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is suitable for basic research on various types of coronary artery disease .

HY-180223

FXIa-IN-17	Factor XI	Cardiovascular Disease
FXIa-IN-17 (Compound FE12) is a selective FXIa inhibitor with an IC₅₀ of 4.4 nM. FXIa-IN-17 effectively inhibits thrombus formation .

HY-179302

SD3A	Mitochondrial Metabolism Integrin	Cardiovascular Disease
SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation .

HY-10280S

YM-60828-d3	Isotope-Labeled Compounds Factor Xa	Others
YM-60828-d₃ is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-19220

S-18326	Thrombin	Cardiovascular Disease
S-18326 is an orally active direct thrombin inhibitor. S-18326 inhibits thrombus formation by reversibly and with high affinity binding to the active site of thrombin, directly preventing the conversion of fibrinogen to fibrin. S-18326 effectively prolongs various clotting times in human plasma. S-18326 has demonstrated antithrombotic efficacy in multiple animal models without causing thrombocytopenia. S-18326 can be used in research on thromboembolic diseases .

HY-106830

Pelrinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC₅₀ of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na ⁺/K ⁺-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .

HY-107588R

TC-I 15 (Standard)	Reference Standards Integrin	Cardiovascular Disease
TC-I 15 (Standard) is the analytical standard of TC-I 15 (HY-107588). This product is intended for research and analytical applications. TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library	1,437 compounds
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,437 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Coagulation and Anti-coagulation Compound Library

1,437 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,437 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Target	Research Area